Universal Technical Institute, Inc. is a Phoenix-based workforce education provider that trains students for careers in transportation, skilled trades, and healthcare through its UTI and Concorde Career Colleges segments. The stock closed Wednesday at $22.04 and was recently trading at $20.57, a decline of 6.67%, after the company reported results for the fiscal fourth quarter ended September 30.
The quarter itself was mixed. Adjusted earnings of $0.32 per share fell roughly 38% short of the consensus estimate near $0.52, while revenue rose 6.0% to $235.9 million and slightly beat expectations. The damage came from the outlook: management guided fiscal 2027 EPS to $0.00 to $0.09, a midpoint of $0.05, against $0.60 in fiscal 2026, and projected GAAP net income of $0 to $5 million.
The shortfall is structural rather than operational. Universal Technical Institute booked about $34.6 million in strategic growth expenses in fiscal 2026, pulling adjusted EBITDA down 19.3% to $102.0 million and cutting full-year net income 46.7% to $33.6 million. Fiscal 2027 carries a similar burden of roughly $35 million tied to four planned campus openings and program expansions, holding adjusted EBITDA flat at $100 million to $106 million.
Revenue guidance of $925 million to $945 million topped the $896 million consensus, but that is cold comfort for investors focused on earnings power. Planned capital spending of $160 million to $170 million signals the profit compression persists through the build-out. Management continues to point to fiscal 2029 targets of more than $1.2 billion in revenue and roughly $220 million in adjusted EBITDA, funded from $320.8 million of available liquidity.
The more concerning disclosure was the slowdown in student starts. Fourth-quarter new starts grew just 3.3% to 12,513, decelerating from 10.9% in the third quarter and 13.8% in the second. End-of-period active students rose 4.4%, versus 8.0% a year earlier. Management attributed the softness to staffing challenges in its high-school admissions channel and constrained program capacity, and said both have been addressed, with the admissions team expanded to more than 185 representatives.
Still, the weaker carry-in explains why fiscal 2027 revenue growth decelerates to roughly 4% even though starts are guided to grow about 9%. That mismatch leaves the growth thesis dependent on execution over the next four quarters.
Sell-side reaction was restrained on ratings but firm on valuations. Lake Street cut its target to $29 from $37 while maintaining a Buy rating, citing implementation risk around the growth investments. B. Riley lowered its target to $39 from $45 and Rosenblatt moved to $35 from $45. Six of seven covering brokerages still rate the shares Buy or better, with a median target near $35. The message: patience may be rewarded, but the payoff has been pushed out.
The move ran against the tape, with the decline entirely company-specific as major U.S. indices traded higher. Trading activity picked up sharply around the release and has run above the roughly 1.4 million-share average daily volume of recent months, consistent with an earnings-driven repricing rather than a technical break.
Technically, the stock slipped just under its 50-day moving average near $20.93 but remains comfortably above its 52-week low of $18.02. It is still far below its 200-day average near $31.91 and about 60% beneath the 52-week high of $51.34, leaving the longer-term trend firmly negative and the shares down roughly 15.7% year to date before today.
The score runs from 0, meaning no meaningful news and a routine price move, to 100, meaning transformative news and an extreme, rare move. UTI earns 51 out of 100.
The verified news was substantial: a quarterly earnings miss combined with guidance implying near-zero fiscal 2027 profit for a company with roughly $1.2 billion in market value. The price move, however, was only about 2.8 times the stock's typical daily swing of roughly 2.4%, and moves of this magnitude or larger occurred three times in the last 60 sessions. Strong news and a moderate anomaly combine into a middling score.
Attention shifts to fiscal first-quarter results, expected in early to mid-February 2027, for evidence that admissions staffing fixes are translating into starts and that new campuses in San Antonio and Atlanta keep pacing ahead of plan. Investors will also watch program-mix trends, since a shift toward shorter, lower-margin skilled-trades offerings pressures revenue per student.
Risks cut both ways. Enrollment recovery could arrive faster than guidance assumes, but continued deceleration, cost overruns on the campus build-out, or further guidance resets would extend the earnings drought. With profits near breakeven, the shares remain highly sensitive to sentiment around the expansion timeline.
Tickeron's Trending AI Robots page showcases a curated selection drawn from hundreds of AI trading bots covering thousands of tickers. Only the strongest performers under current market conditions appear in this section, and the bots differ widely by strategy, timeframe, performance metrics, and traded symbols. Reviewing the featured list is a practical way to see which approaches are working in today's environment. Explore the page to compare the leading performers for yourself.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Oscillator for UTI moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 instances where the indicator moved out of the overbought zone. In 31 of the 39 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 68 cases where UTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UTI as a result. In 76 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence (MACD) for UTI just turned positive on November 10, 2026. Looking at past instances where UTI's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
UTI moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UTI crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +16.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTI advanced for three days, in 259 of 330 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
UTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 183 of 250 cases where UTI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. UTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: UTI's P/B Ratio (3.189) is slightly higher than the industry average of (1.158). UTI has a moderately high P/E Ratio (32.145) as compared to the industry average of (8.484). Projected Growth (PEG Ratio) (1.642) is also within normal values, averaging (1.327). Dividend Yield (0.004) settles around the average of (4.151) among similar stocks. P/S Ratio (1.320) is also within normal values, averaging (27.566).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of technical education
Industry OtherConsumerSpecialties